Northwest Biotherapeutics, Inc. NWBO

NWBO Company Overview

Northwest Biotherapeutics, Inc. is a U.S.-based biotechnology company focused on the development of personalized immune therapies for cancer and other serious diseases. The company operates within the biotechnology and immuno-oncology industries, with its primary emphasis on dendritic cell-based vaccines designed to stimulate a patient’s immune system to target tumors. Northwest Biotherapeutics is publicly traded on the OTC market under the ticker NWBO and has historically concentrated much of its research and development activity on treatments for glioblastoma multiforme (GBM), an aggressive form of brain cancer.

The company’s principal product platform is DCVax, a family of personalized cancer vaccines created from a patient’s own dendritic cells and tumor antigens. Its lead product candidate, DCVax-L, has been evaluated for newly diagnosed glioblastoma, while DCVax-Direct has been studied for inoperable solid tumors. Northwest Biotherapeutics traces its origins to the late 1990s and evolved through acquisitions, licensing arrangements, and internal development focused on cellular immunotherapy technologies. The company’s strategic positioning is centered on individualized cancer treatment approaches and long-duration intellectual property related to dendritic cell vaccine manufacturing and processing.